BMC MUSCULOSKELETAL DISORDERS-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2131664, encodeId=55ee213166435, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：骨科;创伤骨科 经验分享：投稿到接收7周，包含大修1次，接收到在线1周。同行评审提的问题很多，但是都是要害，回答这些问题的过程文章质量提升不少。特点1.这个杂志可以上传很多研究相关数据在补充材料里。特点2.最后回复审稿人意见的回复也会同时上传到线上。总体感觉非常专业严谨，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2af65445426, createdName=ms4000000011622540, createdTime=Thu May 11 18:58:53 CST 2023, time=2023-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1231662, encodeId=1b1812316620b, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肌骨 经验分享：3-20投稿，5月4日一审回来大修，两个审稿人提了几十个问题，很专业，很仔细，对文章提升很有帮助，要求14天回复意见，5月17号返回，6月5号二审意见回来小修，6月9号修回，又耗了一个月，7月8号终于接受，整体耗时4个月不到，速度中等。杂志是老牌杂志，分值确实不高，2022年影响因子升了点，JCR分区却由Q2降到了Q3，骨肌系统专业杂志分值好像都不高，可能是该领域受关注程度有限吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6c575239091, createdName=隐形的翅膀, createdTime=Sun Jul 10 17:45:06 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574107, encodeId=5c7a5e410762, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿周期约3个月：一审2个月，4月投稿，6月中旬审意见小修；6月底返修，7月中旬小修，7月底接收。感觉审稿人比较友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3ce2319891, createdName=Frankey , createdTime=Sun Jul 28 00:10:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071466, encodeId=f5d910e146616, content=亲们，这个期刊可以双通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210822/5ee5b7d9be7f45178a8c9e8ab81c0fee/15c1be4fc836477dbc7045c06baf9dda.jpg, createdBy=606a5581488, createdName=ms9000002129903003, createdTime=Thu Nov 18 16:48:24 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602301, encodeId=82576023011e, content=审稿速度:3.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：arthroscopy;knee 经验分享：审稿人意见很好，编辑也很好，就是版面费太贵。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335d1304552, createdName=zdh198291, createdTime=Mon Jun 15 12:37:36 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997956, encodeId=cd1a99e95626, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿速度较快，但是投稿后没有一本期刊邮寄过来呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9N3mQw4cZ3Kzs6AUTNiccPY2CTV4UL1zuAkObYUjVjwicoXWpl99Ws2wQJhZG1fT7N1icnPLRGdw8G38eFtI0NYFQ/132, createdBy=8e745098341, createdName=145eb10fm24暂无昵称, createdTime=Fri Jul 09 13:13:36 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944970, encodeId=0e0b9449e059, content=我投了一篇，小修，但技术审查都一个多月啦，还没更新怎么回事呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201021/d9653a48518b49e184fb6a8f899f4d5a/859ca74230504d1b94011d885408c7d3.jpg, createdBy=28e71996910, createdName=銧輝怺燳, createdTime=Wed Mar 03 00:07:02 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164004, encodeId=f7b92164004c8, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：生物信息学 经验分享：Publishing and rights Submission status Date Publishing and rights complete 07 Sep 2023 Submission is in publishing and rights 07 Sep 2023 Peer review Submission status Date Submission accepted 05 Sep 2023 Submission under peer review 28 Aug 2023 Submission passed technical check 28 Aug 2023 Amendment received 24 Aug 2023 Amendment received 23 Aug 2023 Revision received 13 Aug 2023 Submission under peer review 25 Feb 2023 Technical check Submission status Date Submission passed technical check 25 Feb 2023 Amendment received 23 Feb 2023 Submission is under technical check 17 Feb 2023 Submission received Submission status Date Submission received 17 Feb 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bad6163337, createdName=ms2000001312611838, createdTime=Fri Oct 20 20:54:30 CST 2023, time=2023-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105980, encodeId=59b421059801b, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：10.16投稿，11.7minor revision, 12.13accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6f46542591, createdName=ms1000001461482475, createdTime=Wed Dec 14 10:10:42 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2091397, encodeId=2884209139edf, content=6月28号投稿，7月18号送审，9月2号翻修，9月16号修回，9月30号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a47d5582368, createdName=ms8000000047057871, createdTime=Sat Oct 01 23:42:43 CST 2022, time=2022-10-01, status=1, ipAttribution=)]

2023-05-11 ms4000000011622540 来自山西省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：骨科;创伤骨科
经验分享：投稿到接收7周，包含大修1次，接收到在线1周。同行评审提的问题很多，但是都是要害，回答这些问题的过程文章质量提升不少。特点1.这个杂志可以上传很多研究相关数据在补充材料里。特点2.最后回复审稿人意见的回复也会同时上传到线上。总体感觉非常专业严谨，效率很高。

102 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131664, encodeId=55ee213166435, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：骨科;创伤骨科 经验分享：投稿到接收7周，包含大修1次，接收到在线1周。同行评审提的问题很多，但是都是要害，回答这些问题的过程文章质量提升不少。特点1.这个杂志可以上传很多研究相关数据在补充材料里。特点2.最后回复审稿人意见的回复也会同时上传到线上。总体感觉非常专业严谨，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2af65445426, createdName=ms4000000011622540, createdTime=Thu May 11 18:58:53 CST 2023, time=2023-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1231662, encodeId=1b1812316620b, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肌骨 经验分享：3-20投稿，5月4日一审回来大修，两个审稿人提了几十个问题，很专业，很仔细，对文章提升很有帮助，要求14天回复意见，5月17号返回，6月5号二审意见回来小修，6月9号修回，又耗了一个月，7月8号终于接受，整体耗时4个月不到，速度中等。杂志是老牌杂志，分值确实不高，2022年影响因子升了点，JCR分区却由Q2降到了Q3，骨肌系统专业杂志分值好像都不高，可能是该领域受关注程度有限吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6c575239091, createdName=隐形的翅膀, createdTime=Sun Jul 10 17:45:06 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574107, encodeId=5c7a5e410762, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿周期约3个月：一审2个月，4月投稿，6月中旬审意见小修；6月底返修，7月中旬小修，7月底接收。感觉审稿人比较友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3ce2319891, createdName=Frankey , createdTime=Sun Jul 28 00:10:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071466, encodeId=f5d910e146616, content=亲们，这个期刊可以双通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210822/5ee5b7d9be7f45178a8c9e8ab81c0fee/15c1be4fc836477dbc7045c06baf9dda.jpg, createdBy=606a5581488, createdName=ms9000002129903003, createdTime=Thu Nov 18 16:48:24 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602301, encodeId=82576023011e, content=审稿速度:3.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：arthroscopy;knee 经验分享：审稿人意见很好，编辑也很好，就是版面费太贵。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335d1304552, createdName=zdh198291, createdTime=Mon Jun 15 12:37:36 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997956, encodeId=cd1a99e95626, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿速度较快，但是投稿后没有一本期刊邮寄过来呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9N3mQw4cZ3Kzs6AUTNiccPY2CTV4UL1zuAkObYUjVjwicoXWpl99Ws2wQJhZG1fT7N1icnPLRGdw8G38eFtI0NYFQ/132, createdBy=8e745098341, createdName=145eb10fm24暂无昵称, createdTime=Fri Jul 09 13:13:36 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944970, encodeId=0e0b9449e059, content=我投了一篇，小修，但技术审查都一个多月啦，还没更新怎么回事呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201021/d9653a48518b49e184fb6a8f899f4d5a/859ca74230504d1b94011d885408c7d3.jpg, createdBy=28e71996910, createdName=銧輝怺燳, createdTime=Wed Mar 03 00:07:02 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164004, encodeId=f7b92164004c8, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：生物信息学 经验分享：Publishing and rights Submission status Date Publishing and rights complete 07 Sep 2023 Submission is in publishing and rights 07 Sep 2023 Peer review Submission status Date Submission accepted 05 Sep 2023 Submission under peer review 28 Aug 2023 Submission passed technical check 28 Aug 2023 Amendment received 24 Aug 2023 Amendment received 23 Aug 2023 Revision received 13 Aug 2023 Submission under peer review 25 Feb 2023 Technical check Submission status Date Submission passed technical check 25 Feb 2023 Amendment received 23 Feb 2023 Submission is under technical check 17 Feb 2023 Submission received Submission status Date Submission received 17 Feb 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bad6163337, createdName=ms2000001312611838, createdTime=Fri Oct 20 20:54:30 CST 2023, time=2023-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105980, encodeId=59b421059801b, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：10.16投稿，11.7minor revision, 12.13accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6f46542591, createdName=ms1000001461482475, createdTime=Wed Dec 14 10:10:42 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2091397, encodeId=2884209139edf, content=6月28号投稿，7月18号送审，9月2号翻修，9月16号修回，9月30号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a47d5582368, createdName=ms8000000047057871, createdTime=Sat Oct 01 23:42:43 CST 2022, time=2022-10-01, status=1, ipAttribution=)]

2022-07-10 隐形的翅膀

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：肌骨
经验分享：3-20投稿，5月4日一审回来大修，两个审稿人提了几十个问题，很专业，很仔细，对文章提升很有帮助，要求14天回复意见，5月17号返回，6月5号二审意见回来小修，6月9号修回，又耗了一个月，7月8号终于接受，整体耗时4个月不到，速度中等。杂志是老牌杂志，分值确实不高，2022年影响因子升了点，JCR分区却由Q2降到了Q3，骨肌系统专业杂志分值好像都不高，可能是该领域受关注程度有限吧

61 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131664, encodeId=55ee213166435, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：骨科;创伤骨科 经验分享：投稿到接收7周，包含大修1次，接收到在线1周。同行评审提的问题很多，但是都是要害，回答这些问题的过程文章质量提升不少。特点1.这个杂志可以上传很多研究相关数据在补充材料里。特点2.最后回复审稿人意见的回复也会同时上传到线上。总体感觉非常专业严谨，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2af65445426, createdName=ms4000000011622540, createdTime=Thu May 11 18:58:53 CST 2023, time=2023-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1231662, encodeId=1b1812316620b, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肌骨 经验分享：3-20投稿，5月4日一审回来大修，两个审稿人提了几十个问题，很专业，很仔细，对文章提升很有帮助，要求14天回复意见，5月17号返回，6月5号二审意见回来小修，6月9号修回，又耗了一个月，7月8号终于接受，整体耗时4个月不到，速度中等。杂志是老牌杂志，分值确实不高，2022年影响因子升了点，JCR分区却由Q2降到了Q3，骨肌系统专业杂志分值好像都不高，可能是该领域受关注程度有限吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6c575239091, createdName=隐形的翅膀, createdTime=Sun Jul 10 17:45:06 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574107, encodeId=5c7a5e410762, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿周期约3个月：一审2个月，4月投稿，6月中旬审意见小修；6月底返修，7月中旬小修，7月底接收。感觉审稿人比较友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3ce2319891, createdName=Frankey , createdTime=Sun Jul 28 00:10:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071466, encodeId=f5d910e146616, content=亲们，这个期刊可以双通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210822/5ee5b7d9be7f45178a8c9e8ab81c0fee/15c1be4fc836477dbc7045c06baf9dda.jpg, createdBy=606a5581488, createdName=ms9000002129903003, createdTime=Thu Nov 18 16:48:24 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602301, encodeId=82576023011e, content=审稿速度:3.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：arthroscopy;knee 经验分享：审稿人意见很好，编辑也很好，就是版面费太贵。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335d1304552, createdName=zdh198291, createdTime=Mon Jun 15 12:37:36 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997956, encodeId=cd1a99e95626, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿速度较快，但是投稿后没有一本期刊邮寄过来呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9N3mQw4cZ3Kzs6AUTNiccPY2CTV4UL1zuAkObYUjVjwicoXWpl99Ws2wQJhZG1fT7N1icnPLRGdw8G38eFtI0NYFQ/132, createdBy=8e745098341, createdName=145eb10fm24暂无昵称, createdTime=Fri Jul 09 13:13:36 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944970, encodeId=0e0b9449e059, content=我投了一篇，小修，但技术审查都一个多月啦，还没更新怎么回事呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201021/d9653a48518b49e184fb6a8f899f4d5a/859ca74230504d1b94011d885408c7d3.jpg, createdBy=28e71996910, createdName=銧輝怺燳, createdTime=Wed Mar 03 00:07:02 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164004, encodeId=f7b92164004c8, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：生物信息学 经验分享：Publishing and rights Submission status Date Publishing and rights complete 07 Sep 2023 Submission is in publishing and rights 07 Sep 2023 Peer review Submission status Date Submission accepted 05 Sep 2023 Submission under peer review 28 Aug 2023 Submission passed technical check 28 Aug 2023 Amendment received 24 Aug 2023 Amendment received 23 Aug 2023 Revision received 13 Aug 2023 Submission under peer review 25 Feb 2023 Technical check Submission status Date Submission passed technical check 25 Feb 2023 Amendment received 23 Feb 2023 Submission is under technical check 17 Feb 2023 Submission received Submission status Date Submission received 17 Feb 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bad6163337, createdName=ms2000001312611838, createdTime=Fri Oct 20 20:54:30 CST 2023, time=2023-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105980, encodeId=59b421059801b, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：10.16投稿，11.7minor revision, 12.13accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6f46542591, createdName=ms1000001461482475, createdTime=Wed Dec 14 10:10:42 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2091397, encodeId=2884209139edf, content=6月28号投稿，7月18号送审，9月2号翻修，9月16号修回，9月30号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a47d5582368, createdName=ms8000000047057871, createdTime=Sat Oct 01 23:42:43 CST 2022, time=2022-10-01, status=1, ipAttribution=)]

2019-07-28 Frankey

审稿速度:3.0 | 投稿命中率:50.0
经验分享：审稿周期约3个月：一审2个月，4月投稿，6月中旬审意见小修；6月底返修，7月中旬小修，7月底接收。感觉审稿人比较友好

137 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131664, encodeId=55ee213166435, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：骨科;创伤骨科 经验分享：投稿到接收7周，包含大修1次，接收到在线1周。同行评审提的问题很多，但是都是要害，回答这些问题的过程文章质量提升不少。特点1.这个杂志可以上传很多研究相关数据在补充材料里。特点2.最后回复审稿人意见的回复也会同时上传到线上。总体感觉非常专业严谨，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2af65445426, createdName=ms4000000011622540, createdTime=Thu May 11 18:58:53 CST 2023, time=2023-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1231662, encodeId=1b1812316620b, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肌骨 经验分享：3-20投稿，5月4日一审回来大修，两个审稿人提了几十个问题，很专业，很仔细，对文章提升很有帮助，要求14天回复意见，5月17号返回，6月5号二审意见回来小修，6月9号修回，又耗了一个月，7月8号终于接受，整体耗时4个月不到，速度中等。杂志是老牌杂志，分值确实不高，2022年影响因子升了点，JCR分区却由Q2降到了Q3，骨肌系统专业杂志分值好像都不高，可能是该领域受关注程度有限吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6c575239091, createdName=隐形的翅膀, createdTime=Sun Jul 10 17:45:06 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574107, encodeId=5c7a5e410762, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿周期约3个月：一审2个月，4月投稿，6月中旬审意见小修；6月底返修，7月中旬小修，7月底接收。感觉审稿人比较友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3ce2319891, createdName=Frankey , createdTime=Sun Jul 28 00:10:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071466, encodeId=f5d910e146616, content=亲们，这个期刊可以双通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210822/5ee5b7d9be7f45178a8c9e8ab81c0fee/15c1be4fc836477dbc7045c06baf9dda.jpg, createdBy=606a5581488, createdName=ms9000002129903003, createdTime=Thu Nov 18 16:48:24 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602301, encodeId=82576023011e, content=审稿速度:3.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：arthroscopy;knee 经验分享：审稿人意见很好，编辑也很好，就是版面费太贵。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335d1304552, createdName=zdh198291, createdTime=Mon Jun 15 12:37:36 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997956, encodeId=cd1a99e95626, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿速度较快，但是投稿后没有一本期刊邮寄过来呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9N3mQw4cZ3Kzs6AUTNiccPY2CTV4UL1zuAkObYUjVjwicoXWpl99Ws2wQJhZG1fT7N1icnPLRGdw8G38eFtI0NYFQ/132, createdBy=8e745098341, createdName=145eb10fm24暂无昵称, createdTime=Fri Jul 09 13:13:36 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944970, encodeId=0e0b9449e059, content=我投了一篇，小修，但技术审查都一个多月啦，还没更新怎么回事呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201021/d9653a48518b49e184fb6a8f899f4d5a/859ca74230504d1b94011d885408c7d3.jpg, createdBy=28e71996910, createdName=銧輝怺燳, createdTime=Wed Mar 03 00:07:02 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164004, encodeId=f7b92164004c8, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：生物信息学 经验分享：Publishing and rights Submission status Date Publishing and rights complete 07 Sep 2023 Submission is in publishing and rights 07 Sep 2023 Peer review Submission status Date Submission accepted 05 Sep 2023 Submission under peer review 28 Aug 2023 Submission passed technical check 28 Aug 2023 Amendment received 24 Aug 2023 Amendment received 23 Aug 2023 Revision received 13 Aug 2023 Submission under peer review 25 Feb 2023 Technical check Submission status Date Submission passed technical check 25 Feb 2023 Amendment received 23 Feb 2023 Submission is under technical check 17 Feb 2023 Submission received Submission status Date Submission received 17 Feb 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bad6163337, createdName=ms2000001312611838, createdTime=Fri Oct 20 20:54:30 CST 2023, time=2023-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105980, encodeId=59b421059801b, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：10.16投稿，11.7minor revision, 12.13accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6f46542591, createdName=ms1000001461482475, createdTime=Wed Dec 14 10:10:42 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2091397, encodeId=2884209139edf, content=6月28号投稿，7月18号送审，9月2号翻修，9月16号修回，9月30号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a47d5582368, createdName=ms8000000047057871, createdTime=Sat Oct 01 23:42:43 CST 2022, time=2022-10-01, status=1, ipAttribution=)]

2021-11-18 ms9000002129903003

亲们，这个期刊可以双通讯吗

46 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131664, encodeId=55ee213166435, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：骨科;创伤骨科 经验分享：投稿到接收7周，包含大修1次，接收到在线1周。同行评审提的问题很多，但是都是要害，回答这些问题的过程文章质量提升不少。特点1.这个杂志可以上传很多研究相关数据在补充材料里。特点2.最后回复审稿人意见的回复也会同时上传到线上。总体感觉非常专业严谨，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2af65445426, createdName=ms4000000011622540, createdTime=Thu May 11 18:58:53 CST 2023, time=2023-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1231662, encodeId=1b1812316620b, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肌骨 经验分享：3-20投稿，5月4日一审回来大修，两个审稿人提了几十个问题，很专业，很仔细，对文章提升很有帮助，要求14天回复意见，5月17号返回，6月5号二审意见回来小修，6月9号修回，又耗了一个月，7月8号终于接受，整体耗时4个月不到，速度中等。杂志是老牌杂志，分值确实不高，2022年影响因子升了点，JCR分区却由Q2降到了Q3，骨肌系统专业杂志分值好像都不高，可能是该领域受关注程度有限吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6c575239091, createdName=隐形的翅膀, createdTime=Sun Jul 10 17:45:06 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574107, encodeId=5c7a5e410762, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿周期约3个月：一审2个月，4月投稿，6月中旬审意见小修；6月底返修，7月中旬小修，7月底接收。感觉审稿人比较友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3ce2319891, createdName=Frankey , createdTime=Sun Jul 28 00:10:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071466, encodeId=f5d910e146616, content=亲们，这个期刊可以双通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210822/5ee5b7d9be7f45178a8c9e8ab81c0fee/15c1be4fc836477dbc7045c06baf9dda.jpg, createdBy=606a5581488, createdName=ms9000002129903003, createdTime=Thu Nov 18 16:48:24 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602301, encodeId=82576023011e, content=审稿速度:3.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：arthroscopy;knee 经验分享：审稿人意见很好，编辑也很好，就是版面费太贵。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335d1304552, createdName=zdh198291, createdTime=Mon Jun 15 12:37:36 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997956, encodeId=cd1a99e95626, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿速度较快，但是投稿后没有一本期刊邮寄过来呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9N3mQw4cZ3Kzs6AUTNiccPY2CTV4UL1zuAkObYUjVjwicoXWpl99Ws2wQJhZG1fT7N1icnPLRGdw8G38eFtI0NYFQ/132, createdBy=8e745098341, createdName=145eb10fm24暂无昵称, createdTime=Fri Jul 09 13:13:36 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944970, encodeId=0e0b9449e059, content=我投了一篇，小修，但技术审查都一个多月啦，还没更新怎么回事呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201021/d9653a48518b49e184fb6a8f899f4d5a/859ca74230504d1b94011d885408c7d3.jpg, createdBy=28e71996910, createdName=銧輝怺燳, createdTime=Wed Mar 03 00:07:02 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164004, encodeId=f7b92164004c8, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：生物信息学 经验分享：Publishing and rights Submission status Date Publishing and rights complete 07 Sep 2023 Submission is in publishing and rights 07 Sep 2023 Peer review Submission status Date Submission accepted 05 Sep 2023 Submission under peer review 28 Aug 2023 Submission passed technical check 28 Aug 2023 Amendment received 24 Aug 2023 Amendment received 23 Aug 2023 Revision received 13 Aug 2023 Submission under peer review 25 Feb 2023 Technical check Submission status Date Submission passed technical check 25 Feb 2023 Amendment received 23 Feb 2023 Submission is under technical check 17 Feb 2023 Submission received Submission status Date Submission received 17 Feb 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bad6163337, createdName=ms2000001312611838, createdTime=Fri Oct 20 20:54:30 CST 2023, time=2023-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105980, encodeId=59b421059801b, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：10.16投稿，11.7minor revision, 12.13accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6f46542591, createdName=ms1000001461482475, createdTime=Wed Dec 14 10:10:42 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2091397, encodeId=2884209139edf, content=6月28号投稿，7月18号送审，9月2号翻修，9月16号修回，9月30号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a47d5582368, createdName=ms8000000047057871, createdTime=Sat Oct 01 23:42:43 CST 2022, time=2022-10-01, status=1, ipAttribution=)]

2020-06-15 zdh198291

审稿速度:3.0 | 投稿命中率:50.0 | 版面费用:2380.0
偏重的研究方向：arthroscopy;knee
经验分享：审稿人意见很好，编辑也很好，就是版面费太贵。

129 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131664, encodeId=55ee213166435, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：骨科;创伤骨科 经验分享：投稿到接收7周，包含大修1次，接收到在线1周。同行评审提的问题很多，但是都是要害，回答这些问题的过程文章质量提升不少。特点1.这个杂志可以上传很多研究相关数据在补充材料里。特点2.最后回复审稿人意见的回复也会同时上传到线上。总体感觉非常专业严谨，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2af65445426, createdName=ms4000000011622540, createdTime=Thu May 11 18:58:53 CST 2023, time=2023-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1231662, encodeId=1b1812316620b, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肌骨 经验分享：3-20投稿，5月4日一审回来大修，两个审稿人提了几十个问题，很专业，很仔细，对文章提升很有帮助，要求14天回复意见，5月17号返回，6月5号二审意见回来小修，6月9号修回，又耗了一个月，7月8号终于接受，整体耗时4个月不到，速度中等。杂志是老牌杂志，分值确实不高，2022年影响因子升了点，JCR分区却由Q2降到了Q3，骨肌系统专业杂志分值好像都不高，可能是该领域受关注程度有限吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6c575239091, createdName=隐形的翅膀, createdTime=Sun Jul 10 17:45:06 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574107, encodeId=5c7a5e410762, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿周期约3个月：一审2个月，4月投稿，6月中旬审意见小修；6月底返修，7月中旬小修，7月底接收。感觉审稿人比较友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3ce2319891, createdName=Frankey , createdTime=Sun Jul 28 00:10:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071466, encodeId=f5d910e146616, content=亲们，这个期刊可以双通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210822/5ee5b7d9be7f45178a8c9e8ab81c0fee/15c1be4fc836477dbc7045c06baf9dda.jpg, createdBy=606a5581488, createdName=ms9000002129903003, createdTime=Thu Nov 18 16:48:24 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602301, encodeId=82576023011e, content=审稿速度:3.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：arthroscopy;knee 经验分享：审稿人意见很好，编辑也很好，就是版面费太贵。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335d1304552, createdName=zdh198291, createdTime=Mon Jun 15 12:37:36 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997956, encodeId=cd1a99e95626, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿速度较快，但是投稿后没有一本期刊邮寄过来呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9N3mQw4cZ3Kzs6AUTNiccPY2CTV4UL1zuAkObYUjVjwicoXWpl99Ws2wQJhZG1fT7N1icnPLRGdw8G38eFtI0NYFQ/132, createdBy=8e745098341, createdName=145eb10fm24暂无昵称, createdTime=Fri Jul 09 13:13:36 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944970, encodeId=0e0b9449e059, content=我投了一篇，小修，但技术审查都一个多月啦，还没更新怎么回事呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201021/d9653a48518b49e184fb6a8f899f4d5a/859ca74230504d1b94011d885408c7d3.jpg, createdBy=28e71996910, createdName=銧輝怺燳, createdTime=Wed Mar 03 00:07:02 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164004, encodeId=f7b92164004c8, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：生物信息学 经验分享：Publishing and rights Submission status Date Publishing and rights complete 07 Sep 2023 Submission is in publishing and rights 07 Sep 2023 Peer review Submission status Date Submission accepted 05 Sep 2023 Submission under peer review 28 Aug 2023 Submission passed technical check 28 Aug 2023 Amendment received 24 Aug 2023 Amendment received 23 Aug 2023 Revision received 13 Aug 2023 Submission under peer review 25 Feb 2023 Technical check Submission status Date Submission passed technical check 25 Feb 2023 Amendment received 23 Feb 2023 Submission is under technical check 17 Feb 2023 Submission received Submission status Date Submission received 17 Feb 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bad6163337, createdName=ms2000001312611838, createdTime=Fri Oct 20 20:54:30 CST 2023, time=2023-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105980, encodeId=59b421059801b, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：10.16投稿，11.7minor revision, 12.13accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6f46542591, createdName=ms1000001461482475, createdTime=Wed Dec 14 10:10:42 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2091397, encodeId=2884209139edf, content=6月28号投稿，7月18号送审，9月2号翻修，9月16号修回，9月30号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a47d5582368, createdName=ms8000000047057871, createdTime=Sat Oct 01 23:42:43 CST 2022, time=2022-10-01, status=1, ipAttribution=)]

2021-07-09 145eb10fm24暂无昵称

审稿速度:3.0 | 投稿命中率:75.0
经验分享：审稿速度较快，但是投稿后没有一本期刊邮寄过来呢

45 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131664, encodeId=55ee213166435, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：骨科;创伤骨科 经验分享：投稿到接收7周，包含大修1次，接收到在线1周。同行评审提的问题很多，但是都是要害，回答这些问题的过程文章质量提升不少。特点1.这个杂志可以上传很多研究相关数据在补充材料里。特点2.最后回复审稿人意见的回复也会同时上传到线上。总体感觉非常专业严谨，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2af65445426, createdName=ms4000000011622540, createdTime=Thu May 11 18:58:53 CST 2023, time=2023-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1231662, encodeId=1b1812316620b, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肌骨 经验分享：3-20投稿，5月4日一审回来大修，两个审稿人提了几十个问题，很专业，很仔细，对文章提升很有帮助，要求14天回复意见，5月17号返回，6月5号二审意见回来小修，6月9号修回，又耗了一个月，7月8号终于接受，整体耗时4个月不到，速度中等。杂志是老牌杂志，分值确实不高，2022年影响因子升了点，JCR分区却由Q2降到了Q3，骨肌系统专业杂志分值好像都不高，可能是该领域受关注程度有限吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6c575239091, createdName=隐形的翅膀, createdTime=Sun Jul 10 17:45:06 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574107, encodeId=5c7a5e410762, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿周期约3个月：一审2个月，4月投稿，6月中旬审意见小修；6月底返修，7月中旬小修，7月底接收。感觉审稿人比较友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3ce2319891, createdName=Frankey , createdTime=Sun Jul 28 00:10:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071466, encodeId=f5d910e146616, content=亲们，这个期刊可以双通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210822/5ee5b7d9be7f45178a8c9e8ab81c0fee/15c1be4fc836477dbc7045c06baf9dda.jpg, createdBy=606a5581488, createdName=ms9000002129903003, createdTime=Thu Nov 18 16:48:24 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602301, encodeId=82576023011e, content=审稿速度:3.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：arthroscopy;knee 经验分享：审稿人意见很好，编辑也很好，就是版面费太贵。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335d1304552, createdName=zdh198291, createdTime=Mon Jun 15 12:37:36 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997956, encodeId=cd1a99e95626, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿速度较快，但是投稿后没有一本期刊邮寄过来呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9N3mQw4cZ3Kzs6AUTNiccPY2CTV4UL1zuAkObYUjVjwicoXWpl99Ws2wQJhZG1fT7N1icnPLRGdw8G38eFtI0NYFQ/132, createdBy=8e745098341, createdName=145eb10fm24暂无昵称, createdTime=Fri Jul 09 13:13:36 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944970, encodeId=0e0b9449e059, content=我投了一篇，小修，但技术审查都一个多月啦，还没更新怎么回事呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201021/d9653a48518b49e184fb6a8f899f4d5a/859ca74230504d1b94011d885408c7d3.jpg, createdBy=28e71996910, createdName=銧輝怺燳, createdTime=Wed Mar 03 00:07:02 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164004, encodeId=f7b92164004c8, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：生物信息学 经验分享：Publishing and rights Submission status Date Publishing and rights complete 07 Sep 2023 Submission is in publishing and rights 07 Sep 2023 Peer review Submission status Date Submission accepted 05 Sep 2023 Submission under peer review 28 Aug 2023 Submission passed technical check 28 Aug 2023 Amendment received 24 Aug 2023 Amendment received 23 Aug 2023 Revision received 13 Aug 2023 Submission under peer review 25 Feb 2023 Technical check Submission status Date Submission passed technical check 25 Feb 2023 Amendment received 23 Feb 2023 Submission is under technical check 17 Feb 2023 Submission received Submission status Date Submission received 17 Feb 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bad6163337, createdName=ms2000001312611838, createdTime=Fri Oct 20 20:54:30 CST 2023, time=2023-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105980, encodeId=59b421059801b, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：10.16投稿，11.7minor revision, 12.13accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6f46542591, createdName=ms1000001461482475, createdTime=Wed Dec 14 10:10:42 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2091397, encodeId=2884209139edf, content=6月28号投稿，7月18号送审，9月2号翻修，9月16号修回，9月30号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a47d5582368, createdName=ms8000000047057871, createdTime=Sat Oct 01 23:42:43 CST 2022, time=2022-10-01, status=1, ipAttribution=)]

2021-03-03 銧輝怺燳

我投了一篇，小修，但技术审查都一个多月啦，还没更新怎么回事呢？

80 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131664, encodeId=55ee213166435, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：骨科;创伤骨科 经验分享：投稿到接收7周，包含大修1次，接收到在线1周。同行评审提的问题很多，但是都是要害，回答这些问题的过程文章质量提升不少。特点1.这个杂志可以上传很多研究相关数据在补充材料里。特点2.最后回复审稿人意见的回复也会同时上传到线上。总体感觉非常专业严谨，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2af65445426, createdName=ms4000000011622540, createdTime=Thu May 11 18:58:53 CST 2023, time=2023-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1231662, encodeId=1b1812316620b, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肌骨 经验分享：3-20投稿，5月4日一审回来大修，两个审稿人提了几十个问题，很专业，很仔细，对文章提升很有帮助，要求14天回复意见，5月17号返回，6月5号二审意见回来小修，6月9号修回，又耗了一个月，7月8号终于接受，整体耗时4个月不到，速度中等。杂志是老牌杂志，分值确实不高，2022年影响因子升了点，JCR分区却由Q2降到了Q3，骨肌系统专业杂志分值好像都不高，可能是该领域受关注程度有限吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6c575239091, createdName=隐形的翅膀, createdTime=Sun Jul 10 17:45:06 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574107, encodeId=5c7a5e410762, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿周期约3个月：一审2个月，4月投稿，6月中旬审意见小修；6月底返修，7月中旬小修，7月底接收。感觉审稿人比较友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3ce2319891, createdName=Frankey , createdTime=Sun Jul 28 00:10:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071466, encodeId=f5d910e146616, content=亲们，这个期刊可以双通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210822/5ee5b7d9be7f45178a8c9e8ab81c0fee/15c1be4fc836477dbc7045c06baf9dda.jpg, createdBy=606a5581488, createdName=ms9000002129903003, createdTime=Thu Nov 18 16:48:24 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602301, encodeId=82576023011e, content=审稿速度:3.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：arthroscopy;knee 经验分享：审稿人意见很好，编辑也很好，就是版面费太贵。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335d1304552, createdName=zdh198291, createdTime=Mon Jun 15 12:37:36 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997956, encodeId=cd1a99e95626, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿速度较快，但是投稿后没有一本期刊邮寄过来呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9N3mQw4cZ3Kzs6AUTNiccPY2CTV4UL1zuAkObYUjVjwicoXWpl99Ws2wQJhZG1fT7N1icnPLRGdw8G38eFtI0NYFQ/132, createdBy=8e745098341, createdName=145eb10fm24暂无昵称, createdTime=Fri Jul 09 13:13:36 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944970, encodeId=0e0b9449e059, content=我投了一篇，小修，但技术审查都一个多月啦，还没更新怎么回事呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201021/d9653a48518b49e184fb6a8f899f4d5a/859ca74230504d1b94011d885408c7d3.jpg, createdBy=28e71996910, createdName=銧輝怺燳, createdTime=Wed Mar 03 00:07:02 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164004, encodeId=f7b92164004c8, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：生物信息学 经验分享：Publishing and rights Submission status Date Publishing and rights complete 07 Sep 2023 Submission is in publishing and rights 07 Sep 2023 Peer review Submission status Date Submission accepted 05 Sep 2023 Submission under peer review 28 Aug 2023 Submission passed technical check 28 Aug 2023 Amendment received 24 Aug 2023 Amendment received 23 Aug 2023 Revision received 13 Aug 2023 Submission under peer review 25 Feb 2023 Technical check Submission status Date Submission passed technical check 25 Feb 2023 Amendment received 23 Feb 2023 Submission is under technical check 17 Feb 2023 Submission received Submission status Date Submission received 17 Feb 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bad6163337, createdName=ms2000001312611838, createdTime=Fri Oct 20 20:54:30 CST 2023, time=2023-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105980, encodeId=59b421059801b, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：10.16投稿，11.7minor revision, 12.13accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6f46542591, createdName=ms1000001461482475, createdTime=Wed Dec 14 10:10:42 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2091397, encodeId=2884209139edf, content=6月28号投稿，7月18号送审，9月2号翻修，9月16号修回，9月30号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a47d5582368, createdName=ms8000000047057871, createdTime=Sat Oct 01 23:42:43 CST 2022, time=2022-10-01, status=1, ipAttribution=)]

2023-10-20 ms2000001312611838

审稿速度:3.0 | 投稿命中率:95.0
偏重的研究方向：生物信息学
经验分享：Publishing and rights
Submission status Date
Publishing and rights complete
07 Sep 2023
Submission is in publishing and rights
07 Sep 2023
Peer review
Submission status Date
Submission accepted
05 Sep 2023
Submission under peer review
28 Aug 2023
Submission passed technical check
28 Aug 2023
Amendment received
24 Aug 2023
Amendment received
23 Aug 2023
Revision received
13 Aug 2023
Submission under peer review
25 Feb 2023
Technical check
Submission status Date
Submission passed technical check
25 Feb 2023
Amendment received
23 Feb 2023
Submission is under technical check
17 Feb 2023
Submission received
Submission status Date
Submission received
17 Feb 2023

66 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131664, encodeId=55ee213166435, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：骨科;创伤骨科 经验分享：投稿到接收7周，包含大修1次，接收到在线1周。同行评审提的问题很多，但是都是要害，回答这些问题的过程文章质量提升不少。特点1.这个杂志可以上传很多研究相关数据在补充材料里。特点2.最后回复审稿人意见的回复也会同时上传到线上。总体感觉非常专业严谨，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2af65445426, createdName=ms4000000011622540, createdTime=Thu May 11 18:58:53 CST 2023, time=2023-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1231662, encodeId=1b1812316620b, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肌骨 经验分享：3-20投稿，5月4日一审回来大修，两个审稿人提了几十个问题，很专业，很仔细，对文章提升很有帮助，要求14天回复意见，5月17号返回，6月5号二审意见回来小修，6月9号修回，又耗了一个月，7月8号终于接受，整体耗时4个月不到，速度中等。杂志是老牌杂志，分值确实不高，2022年影响因子升了点，JCR分区却由Q2降到了Q3，骨肌系统专业杂志分值好像都不高，可能是该领域受关注程度有限吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6c575239091, createdName=隐形的翅膀, createdTime=Sun Jul 10 17:45:06 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574107, encodeId=5c7a5e410762, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿周期约3个月：一审2个月，4月投稿，6月中旬审意见小修；6月底返修，7月中旬小修，7月底接收。感觉审稿人比较友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3ce2319891, createdName=Frankey , createdTime=Sun Jul 28 00:10:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071466, encodeId=f5d910e146616, content=亲们，这个期刊可以双通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210822/5ee5b7d9be7f45178a8c9e8ab81c0fee/15c1be4fc836477dbc7045c06baf9dda.jpg, createdBy=606a5581488, createdName=ms9000002129903003, createdTime=Thu Nov 18 16:48:24 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602301, encodeId=82576023011e, content=审稿速度:3.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：arthroscopy;knee 经验分享：审稿人意见很好，编辑也很好，就是版面费太贵。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335d1304552, createdName=zdh198291, createdTime=Mon Jun 15 12:37:36 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997956, encodeId=cd1a99e95626, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿速度较快，但是投稿后没有一本期刊邮寄过来呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9N3mQw4cZ3Kzs6AUTNiccPY2CTV4UL1zuAkObYUjVjwicoXWpl99Ws2wQJhZG1fT7N1icnPLRGdw8G38eFtI0NYFQ/132, createdBy=8e745098341, createdName=145eb10fm24暂无昵称, createdTime=Fri Jul 09 13:13:36 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944970, encodeId=0e0b9449e059, content=我投了一篇，小修，但技术审查都一个多月啦，还没更新怎么回事呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201021/d9653a48518b49e184fb6a8f899f4d5a/859ca74230504d1b94011d885408c7d3.jpg, createdBy=28e71996910, createdName=銧輝怺燳, createdTime=Wed Mar 03 00:07:02 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164004, encodeId=f7b92164004c8, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：生物信息学 经验分享：Publishing and rights Submission status Date Publishing and rights complete 07 Sep 2023 Submission is in publishing and rights 07 Sep 2023 Peer review Submission status Date Submission accepted 05 Sep 2023 Submission under peer review 28 Aug 2023 Submission passed technical check 28 Aug 2023 Amendment received 24 Aug 2023 Amendment received 23 Aug 2023 Revision received 13 Aug 2023 Submission under peer review 25 Feb 2023 Technical check Submission status Date Submission passed technical check 25 Feb 2023 Amendment received 23 Feb 2023 Submission is under technical check 17 Feb 2023 Submission received Submission status Date Submission received 17 Feb 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bad6163337, createdName=ms2000001312611838, createdTime=Fri Oct 20 20:54:30 CST 2023, time=2023-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105980, encodeId=59b421059801b, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：10.16投稿，11.7minor revision, 12.13accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6f46542591, createdName=ms1000001461482475, createdTime=Wed Dec 14 10:10:42 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2091397, encodeId=2884209139edf, content=6月28号投稿，7月18号送审，9月2号翻修，9月16号修回，9月30号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a47d5582368, createdName=ms8000000047057871, createdTime=Sat Oct 01 23:42:43 CST 2022, time=2022-10-01, status=1, ipAttribution=)]

2022-12-14 ms1000001461482475 来自北京

审稿速度:3.0 | 投稿命中率:75.0
经验分享：10.16投稿，11.7minor revision, 12.13accept

196 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2131664, encodeId=55ee213166435, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：骨科;创伤骨科 经验分享：投稿到接收7周，包含大修1次，接收到在线1周。同行评审提的问题很多，但是都是要害，回答这些问题的过程文章质量提升不少。特点1.这个杂志可以上传很多研究相关数据在补充材料里。特点2.最后回复审稿人意见的回复也会同时上传到线上。总体感觉非常专业严谨，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2af65445426, createdName=ms4000000011622540, createdTime=Thu May 11 18:58:53 CST 2023, time=2023-05-11, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1231662, encodeId=1b1812316620b, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肌骨 经验分享：3-20投稿，5月4日一审回来大修，两个审稿人提了几十个问题，很专业，很仔细，对文章提升很有帮助，要求14天回复意见，5月17号返回，6月5号二审意见回来小修，6月9号修回，又耗了一个月，7月8号终于接受，整体耗时4个月不到，速度中等。杂志是老牌杂志，分值确实不高，2022年影响因子升了点，JCR分区却由Q2降到了Q3，骨肌系统专业杂志分值好像都不高，可能是该领域受关注程度有限吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6c575239091, createdName=隐形的翅膀, createdTime=Sun Jul 10 17:45:06 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574107, encodeId=5c7a5e410762, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：审稿周期约3个月：一审2个月，4月投稿，6月中旬审意见小修；6月底返修，7月中旬小修，7月底接收。感觉审稿人比较友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3ce2319891, createdName=Frankey , createdTime=Sun Jul 28 00:10:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071466, encodeId=f5d910e146616, content=亲们，这个期刊可以双通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210822/5ee5b7d9be7f45178a8c9e8ab81c0fee/15c1be4fc836477dbc7045c06baf9dda.jpg, createdBy=606a5581488, createdName=ms9000002129903003, createdTime=Thu Nov 18 16:48:24 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602301, encodeId=82576023011e, content=审稿速度:3.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：arthroscopy;knee 经验分享：审稿人意见很好，编辑也很好，就是版面费太贵。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=335d1304552, createdName=zdh198291, createdTime=Mon Jun 15 12:37:36 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997956, encodeId=cd1a99e95626, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：审稿速度较快，但是投稿后没有一本期刊邮寄过来呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/9N3mQw4cZ3Kzs6AUTNiccPY2CTV4UL1zuAkObYUjVjwicoXWpl99Ws2wQJhZG1fT7N1icnPLRGdw8G38eFtI0NYFQ/132, createdBy=8e745098341, createdName=145eb10fm24暂无昵称, createdTime=Fri Jul 09 13:13:36 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944970, encodeId=0e0b9449e059, content=我投了一篇，小修，但技术审查都一个多月啦，还没更新怎么回事呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201021/d9653a48518b49e184fb6a8f899f4d5a/859ca74230504d1b94011d885408c7d3.jpg, createdBy=28e71996910, createdName=銧輝怺燳, createdTime=Wed Mar 03 00:07:02 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164004, encodeId=f7b92164004c8, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：生物信息学 经验分享：Publishing and rights Submission status Date Publishing and rights complete 07 Sep 2023 Submission is in publishing and rights 07 Sep 2023 Peer review Submission status Date Submission accepted 05 Sep 2023 Submission under peer review 28 Aug 2023 Submission passed technical check 28 Aug 2023 Amendment received 24 Aug 2023 Amendment received 23 Aug 2023 Revision received 13 Aug 2023 Submission under peer review 25 Feb 2023 Technical check Submission status Date Submission passed technical check 25 Feb 2023 Amendment received 23 Feb 2023 Submission is under technical check 17 Feb 2023 Submission received Submission status Date Submission received 17 Feb 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bad6163337, createdName=ms2000001312611838, createdTime=Fri Oct 20 20:54:30 CST 2023, time=2023-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105980, encodeId=59b421059801b, content=审稿速度:3.0 | 投稿命中率:75.0 经验分享：10.16投稿，11.7minor revision, 12.13accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c6f46542591, createdName=ms1000001461482475, createdTime=Wed Dec 14 10:10:42 CST 2022, time=2022-12-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2091397, encodeId=2884209139edf, content=6月28号投稿，7月18号送审，9月2号翻修，9月16号修回，9月30号接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a47d5582368, createdName=ms8000000047057871, createdTime=Sat Oct 01 23:42:43 CST 2022, time=2022-10-01, status=1, ipAttribution=)]

2022-10-01 ms8000000047057871

6月28号投稿，7月18号送审，9月2号翻修，9月16号修回，9月30号接收。

61 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务